<br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

A Quick Review of the History of Hormone Sensitive Metastatic Prostate Cancer

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Early Chemo+ADT: A debate in one slide – a need for randomized phase 3 trial

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

The CHAARTED Hypothesis

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

E3805 – CHAARTED Treatment

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Key Eligibility Criteria

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Study Endpoints

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Statistical Design: History of CHAARTED<br />Intent to treat analysis, 80% power 1-sided alpha=2.5% to detect 33% improvement in median OS (with all versions)

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Results:

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Patient characteristics

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Patient characteristics

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Patient characteristics

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Primary endpoint: Overall survival

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Causes of Death

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

OS by extent of metastatic disease at start of ADT

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

ADT + Docetaxel benefited all subgroups

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Secondary Endpoints

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Therapy beyond progression

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Chemotherapy Doses Given

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Non-Hematologic Toxicity (%)

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Hematologic Toxicity (%)

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Conclusion

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Clinical interpretation

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

Designed and conducted by:

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting